[go: up one dir, main page]

BR0109770A - Use of galantamine to treat neuropsychiatric behavior associated with alzheimer's disease - Google Patents

Use of galantamine to treat neuropsychiatric behavior associated with alzheimer's disease

Info

Publication number
BR0109770A
BR0109770A BR0109770-9A BR0109770A BR0109770A BR 0109770 A BR0109770 A BR 0109770A BR 0109770 A BR0109770 A BR 0109770A BR 0109770 A BR0109770 A BR 0109770A
Authority
BR
Brazil
Prior art keywords
alzheimer
galantamine
disease
behavior associated
treat neuropsychiatric
Prior art date
Application number
BR0109770-9A
Other languages
Portuguese (pt)
Inventor
Win Louis Julien Parys
Michael Pontecorvo
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR0109770A publication Critical patent/BR0109770A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

"USO DE GALANTAMINA PARA O TRATAMENTO DO COMPORTAMENTO NEUROPSIQUIáTRICO ASSOCIADO COM A DOENçA DE ALZHEIMER". A invenção refere-se a galantamina que tem sido utilizada no tratamento de um número de doenças crónicas. Foi descoberto que a galantamina é segura e eficiente no tratamento da doença de Alzheimer. Os distúrbios neuropsiquiátricos são freq³entemente associados com a doença de Alzheimer. é demonstrado que a galantamina é também eficiente na redução ou na estabilização da incidência do comportamento neuropsiquiátrico observado nos pacientes com Alzheimer."USE OF GALANTAMIN FOR TREATMENT OF NEUROPSYCHIATRIC BEHAVIOR ASSOCIATED WITH ALZHEIMER DISEASE". The invention relates to galantamine which has been used in the treatment of a number of chronic diseases. Galantamine has been found to be safe and effective in treating Alzheimer's disease. Neuropsychiatric disorders are often associated with Alzheimer's disease. galantamine is also shown to be effective in reducing or stabilizing the incidence of neuropsychiatric behavior observed in Alzheimer's patients.

BR0109770-9A 2000-04-03 2001-03-28 Use of galantamine to treat neuropsychiatric behavior associated with alzheimer's disease BR0109770A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19425900P 2000-04-03 2000-04-03
PCT/EP2001/003553 WO2001074339A2 (en) 2000-04-03 2001-03-28 A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease

Publications (1)

Publication Number Publication Date
BR0109770A true BR0109770A (en) 2003-02-04

Family

ID=22716898

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0109770-9A BR0109770A (en) 2000-04-03 2001-03-28 Use of galantamine to treat neuropsychiatric behavior associated with alzheimer's disease

Country Status (20)

Country Link
EP (1) EP1272192A2 (en)
JP (1) JP2003528913A (en)
KR (1) KR20020086911A (en)
CN (1) CN1430514A (en)
AU (2) AU2001265844B2 (en)
BG (1) BG107093A (en)
BR (1) BR0109770A (en)
CA (1) CA2310926C (en)
CZ (1) CZ20023543A3 (en)
EE (1) EE200200554A (en)
HR (1) HRP20020778A2 (en)
HU (1) HUP0300566A3 (en)
IL (1) IL152061A0 (en)
MX (1) MXPA02009777A (en)
NO (1) NO20024746L (en)
PL (1) PL361272A1 (en)
RU (1) RU2002129298A (en)
SK (1) SK15422002A3 (en)
WO (1) WO2001074339A2 (en)
ZA (1) ZA200207935B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
DE602004009195T2 (en) * 2003-07-25 2008-06-26 F. Hoffmann-La Roche Ag COMBINATION OF A MGLUR2 ANTAGONISTS AND AN AXIS INHIBITOR FOR THE TREATMENT OF ACUTE AND / OR CHRONIC NEUROLOGICAL DISEASES
DE10338544B4 (en) * 2003-08-19 2017-08-31 Janssen Pharmaceutica N.V. Buccal formulations of galanthamine and their applications
WO2009120277A1 (en) 2008-03-27 2009-10-01 Chase Pharmaceuticals Corporation Use and composition for treating dementia
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
BG66818B1 (en) * 2013-03-07 2019-01-31 Berbee Beheer B. V. Composition of hippeastrum papilio extract for the production of medicines and nutritional supplements
CN107847504A (en) * 2015-05-18 2018-03-27 斯奈普泰克发展有限责任公司 Galantamine clearance of amyloid beta
CN117957003A (en) * 2021-09-09 2024-04-30 上海日馨医药科技股份有限公司 Methods for treating neurodegenerative diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE19509663A1 (en) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Process for the isolation of galanthamine
GB9600080D0 (en) * 1996-01-04 1996-03-06 Chiroscience Ltd Resolution process
CA2351347A1 (en) 1998-11-23 2000-06-02 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
EE04996B1 (en) * 1998-12-24 2008-04-15 Janssen Pharmaceutica N.V. Controlled release galantamine preparation, method of preparation, dosage form and pharmaceutical packaging
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects
CA2310990A1 (en) * 2000-04-03 2000-10-09 Michael Pontecorvo A use of galantamine for the treatment of alzheimer's disease; targeting the underlying cause of the disease

Also Published As

Publication number Publication date
BG107093A (en) 2003-06-30
IL152061A0 (en) 2003-05-29
AU2001265844B2 (en) 2005-04-14
CZ20023543A3 (en) 2003-03-12
AU6584401A (en) 2001-10-15
CN1430514A (en) 2003-07-16
WO2001074339A3 (en) 2002-09-12
NO20024746D0 (en) 2002-10-02
CA2310926C (en) 2002-10-15
PL361272A1 (en) 2004-10-04
HRP20020778A2 (en) 2004-04-30
EE200200554A (en) 2004-04-15
EP1272192A2 (en) 2003-01-08
WO2001074339A2 (en) 2001-10-11
KR20020086911A (en) 2002-11-20
MXPA02009777A (en) 2003-03-27
ZA200207935B (en) 2004-01-30
HUP0300566A3 (en) 2004-10-28
NO20024746L (en) 2002-11-28
CA2310926A1 (en) 2000-10-04
SK15422002A3 (en) 2003-04-01
HUP0300566A2 (en) 2003-06-28
JP2003528913A (en) 2003-09-30
RU2002129298A (en) 2004-03-27

Similar Documents

Publication Publication Date Title
BR0012136A (en) Highly selective norepinephrine reabsorption inhibitors and methods of using them
BR9807673A (en) Processes to treat allergic asthma and dermatitis in a human and pharmaceutical composition.
BR0115109A (en) Therapeutic agents and methods of their use for angiogenesis modulation
DK0713701T3 (en) 2-Bromelatonin for the treatment of sleep disorders
BR0013122A (en) Cyclobenzaprine for treatment of generalized anxiety disorder and cyclobenzaprine compositions
WO2002002518A3 (en) Compounds to treat alzheimer's disease
BR0114913A (en) Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
BR0111913A (en) Gabapentin analogs for sleep disorders
WO2002002520A3 (en) Compounds to treat alzheimer's disease
KR970704429A (en) USE OF DROLOXIFENE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
BR0312845A (en) Tetrapropylammonium tetrathiomolybdate and related compounds for antiangiogenic therapies
BR9509006A (en) Composition for topical application to the skin pharmaceutical composition use of a cholesterol synthesis inhibitor and process for the treatment of mitigation or prevention of skin disorders
BR0109770A (en) Use of galantamine to treat neuropsychiatric behavior associated with alzheimer's disease
NO20033443L (en) Use of CD-2 binding agents in the treatment or prevention of skin disorders
KR890011589A (en) Use of Benzamide
BR0208405A (en) Cyan-substituted dihydropyrimine compounds and their use to treat disease
BR9812660A (en) Compositions and methods for treating respiratory disorders
BR0112547A (en) Process for finding compounds that are suitable for obesity treatment and / or prophylaxis
BRPI0410654A (en) compound, pharmaceutical composition, use of a compound, method for treating a disorder of a patient, and process for the preparation of a compound
BR9813549A (en) Process for prevention and treatment of myocardium affected by injury
BR0107960A (en) Treatment of allergic and inflammatory conditions
BR0207866A (en) Use of flumazenil in the preparation of a drug for the treatment of cocaine addiction
BR9908885A (en) Medicinal product for prophylaxis and / or treatment of mastocarcinoma, comprising a steroid aromatase inhibitor
DE3875349D1 (en) GLYCOSAMINOGLYCAN FOR TREATING DIABETIC MICROANGIOPATHY.
NO990450L (en) Treatment of mental disorders

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2016 DE 25/08/2009